Novartis AG is 182.5x more valuable than AbCellera Biologics Inc. by market capitalization ($293.70 B vs $1.61 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ABCL | NVS |
|---|---|---|
| Market cap | $1.61 B | $293.70 B |
| US-listed rank | #2274 | #46 |
| Revenue (latest FY) | $75.13M | - |
| Net income (latest FY) | -$146.41M | - |
| Net margin | -194.9% | - |
| SEC filings | 297 | 947 |
Novartis AG is 182.5x more valuable than AbCellera Biologics Inc. by market capitalization ($293.70 B vs $1.61 B).
Full pages: AbCellera Biologics Inc. and Novartis AG, or browse the full rankings.